Advancing public health through partnerships.(Food and Drug Administration)

From: FDA Consumer | Date: September 1, 2006| Author: Meadows, Michelle; Weitzman, Mitchell | Copyright information

Whether the goal is ensuring the safety of the food supply or speeding the development of new medical treatments, the Food and Drug Administration often depends on its strong relationships with other organizations. Health care providers, regulated industry, members of academia, other government agencies, and consumers all contribute their expertise and experiences when the FDA tackles complex scientific issues.

"Our collaborations are an essential part of the FDA's long...

Read all of this article with a FREE trial to HighBeam Research

Related newspaper, magazine, and journal articles from HighBeam Research

Patient death leads FDA to suspend gene therapy study.(Drug Safety)(Food and Drug Administration)
Adverse Event Reporting News ; FDA has suspended a Seattle company's gene therapy study after learning that a patient died, The Associated Press (AP) reported July 26. Targeted Genetics, which notified FDA of the patient's illness and subsequent death, had enrolled more than 100 people in a study of gene therapy for advanced
SAFETY OF GENE THERAPY:JAY P. SIEGEL
Congressional Testimony ; 00-00-0000 STATEMENT OF JAY P. SIEGEL, M.D. FEBRUARY 2, 2000 INTRODUCTION Good morning, Mr. Chairman and Members of the Committee. Thank you for inviting the Food and Drug Administration (FDA or the Agency) to participate in this hearing concerning gene therapy and the Federal governments role in
HUMAN GENE THERAPY: Harsh Lessons, High Hopes.(gene therapy has not lived up to its initial high hopes, but the future is looking more promising)
FDA Consumer ; ... others. The inquiries provided disappointing news: Gene therapy researchers were not following ... percent of the serious adverse events. The news hit the clinical trial community like a ... ongoing. Signs of Progress Not all the news about gene therapy is bad. It's true that ...
Arizona teenager dies after receiving experimental gene therapy treatment; FDA says rules were violated.
Transplant News ; An Arizona teenager who died days after receiving experimental gene therapy never should have been part of the study, and the researchers conducting the trials violated at least 2 rules, according to officials with the Food and Drug Administration (FDA). Speaking at a hearing of the National
SAFETY OF GENE THERAPY:H. STEWART PARKER
Congressional Testimony ; 00-00-0000 TESTIMONY OF H. STEWART PARKER JANUARY 26, 2000 Good morning. I am Stewart Parker, CEO of Targeted Genetics Corporation, a biotechnology company based in Seattle, Washington. I am testifying on behalf of the Biotechnology Industry Organization (BIO), which represents 850 companies,
Resumption of Gene Therapy Urged; Advisory Panel Backs Restrictions After Treatment Triggered French Boy's Illness
The Washington Post ; New tests offer overwhelming evidence that a leukemia-like disease diagnosed in a 3-year-old boy in France was triggered by the experimental gene therapy he received as a baby, the first proof that the nascent and troubled field of medicine can cause cancer. Nonetheless, because of the treatment's
Victim's Dad Faults Gene Therapy Team; Researchers Misled Family of Teen About Risks, Senate Oversight Panel Is Told
The Washington Post ; His voice trembling with emotion, the father of the teenager who died in a gene therapy experiment in September told a rapt Senate subcommittee yesterday that the University of Pennsylvania scientists who conducted the research oversold its potential benefits and underplayed its risks. A
FDA panel recommends curtailing selected gene therapy trials.
Transplant News ; ... otherwise successful treatment with gene therapy for X-linked severe combined immunodeficiency syndrome (x-SCID). (Transplant News, January 31, 2003) The committee recommended that the gene therapy technique be allowed if the therapy represents the only hope ...
DR. ISNER'S PATIENTS URGE SUPPORT.(Jeffrey Isner, gene therapy for heart disease)
Medical Update ; Editor's note: In late February 1998, retired insurance executive John W. Jack Gardiner of Naples, Florida, became the first patient to undergo experimental coronary gene therapy at the Boston-based St. Elizabeth's Medical Center (see last issue). Two years later, Jack Gardiner is not only alive
Penn researchers tell FDA gene therapy procedures did not contribute to patient's death.
Transplant News ; In a vigorous defense of their suspended gene therapy program, officials at the University of Pennsylvania said that while there were administrative lapses, these were little more than minor deviations in bookkeeping and in no way contributed to the death of an 18-year-old patient. In a 28-page